{"id":"linezolid-lzd","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Thrombocytopenia"},{"rate":"1-2%","effect":"Anemia"},{"rate":"3-10%","effect":"Nausea"},{"rate":"2-11%","effect":"Diarrhea"},{"rate":"0.5-11%","effect":"Headache"},{"rate":"0.3-2.4%","effect":"Peripheral neuropathy (with prolonged use)"},{"rate":"0.3-1%","effect":"Optic neuropathy (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL126","moleculeType":"Small molecule","molecularWeight":"337.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linezolid is an oxazolidinone antibiotic that binds to the bacterial 23S rRNA component of the 50S ribosomal subunit, blocking the formation of the initiation complex required for protein synthesis. This bacteriostatic action is effective against a broad range of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Its unique mechanism allows it to penetrate tissues well and achieve good intracellular concentrations.","oneSentence":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:17.478Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Methicillin-resistant Staphylococcus aureus (MRSA) infections"},{"name":"Vancomycin-resistant Enterococcus faecium (VRE) infections"},{"name":"Gram-positive bacterial infections including pneumonia and skin infections"}]},"trialDetails":[{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT07301294","phase":"PHASE4","title":"Microbiological Characteristics of Biofilm on Double J Ureteral Stents After Lithotripsy.","status":"NOT_YET_RECRUITING","sponsor":"Menoufia University","startDate":"2026-01-01","conditions":"Double J Stent","enrollment":100},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":"Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":120},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Treat to Target, Treatment Duration","enrollment":52},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT05007821","phase":"PHASE2","title":"Linezolid Dosing Strategies in Drug-Resistant TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-11","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary","enrollment":138},{"nctId":"NCT06761131","phase":"","title":"Compare Linezolid-Induced Thrombocytopenia in Patients With Normal Renal Function Versus Impaired Renal Function","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-05-20","conditions":"Thrombocytopaenia, Impaired Renal Function","enrollment":60},{"nctId":"NCT05069974","phase":"PHASE3","title":"Alternative Antibiotics for Syphilis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2021-10-14","conditions":"Early Latent Syphilis, Primary Syphilis, Secondary Syphilis","enrollment":224},{"nctId":"NCT06921213","phase":"PHASE2","title":"Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis","status":"NOT_YET_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-10-01","conditions":"Syphilis, Congenital","enrollment":90},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":220},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT06811025","phase":"PHASE1, PHASE2","title":"Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2024-02-01","conditions":"Tuberculosis, Meningitis","enrollment":24},{"nctId":"NCT06811012","phase":"PHASE1, PHASE2","title":"Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2024-01-31","conditions":"Tuberculosis, Bone, Joint","enrollment":24},{"nctId":"NCT04717908","phase":"NA","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2021-01-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":89},{"nctId":"NCT04021121","phase":"PHASE2","title":"Adjunctive Linezolid for the Treatment of Tuberculous Meningitis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-05","conditions":"Tuberculosis, Meningeal","enrollment":40},{"nctId":"NCT06476210","phase":"PHASE4","title":"The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2024-06","conditions":"Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":"Staphylococcus Aureus","enrollment":265},{"nctId":"NCT05040126","phase":"PHASE3","title":"Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2021-10-07","conditions":"Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB, Non-responsive Multidrug-Resistant Pulmonary TB","enrollment":400},{"nctId":"NCT05306223","phase":"PHASE4","title":"A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-05-10","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":212},{"nctId":"NCT03830671","phase":"PHASE4","title":"The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2019-03-08","conditions":"Multi-drug Resistant Tuberculosis","enrollment":515},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT00727844","phase":"PHASE2","title":"Linezolid to Treat Extensively-Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Linezolid (LZD)","genericName":"Linezolid (LZD)","companyName":"Wuhan Pulmonary Hospital","companyId":"wuhan-pulmonary-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Methicillin-resistant Staphylococcus aureus (MRSA) infections, Vancomycin-resistant Enterococcus (VRE) infections, Gram-positive bacterial infections including pneumonia and skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}